Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung cancer model

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 1, 2014, Pages 69-73

  Mu, Xiao Yan ^a   Dong, Xue Li ^a   Sun, Jie ^a   Ni, Yu Hua ^a   Dong, Zhang ^a   Li, Xi Li ^a   Sun, Er Lian ^a   Yi, Zhou ^a   Li, Gao ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Celecoxib; Combination therapy; Erlotinib; Lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; SULFONAMIDE;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CHEMISTRY; DRUG COMBINATION; DRUG POTENTIATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84894090446     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.1.69     Document Type: Article

References (15)

1. Ali S, El-Rayes BF, Sarkar FH, Philip PA (2005). Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther, 4, 1943-51.
2. Brunelle JK, Letai A (2009). Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci, 122, 437-41.
3. Chan G, Boyle JO, Yang EK, et al (2003). Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res, 59, 991-4.
4. Choe MS, Zhang X, Shin HJ, Shin DM, Chen ZG (2005). Interaction between epidermal growth factor receptor-and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther, 4, 1448-55.
5. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R (2003). FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist, 8, 303-6.
6. Dannenberg AJ, Subbaramaiah K (2003). Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell, 4, 431-6.
7. Fu S, Rivera M, Ko EC, et al (2011). Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 as a novel approach to enhance radiotherapy. J Cell Sci Ther, 1, S1-002.
8. Gerber DE (2008). EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. Drug Dev Res, 69, 359-72.
9. Jalili A, Pinc A, Pieczkowski F, Karlhofer FM, Stingl G, Wagner SN (2008). Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges, 6, 1066-9.
10. Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics, 2008. CA Cancer J Clin, 58, 71-96.
11. Katzel JA, Fanucchi MP, Li Z (2009). Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol, 2, 2.
12. Renkonen J, Wolff H, Paavonen T (2002). Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch, 440, 594-7.
13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32.
14. Torrance CJ, Jackson PE, Montgomery E, et al (2000). Combinatorial chemoprevention of intestinal neoplasia. Nat Med, 6, 1024-8.
15. Zhang X, Chen ZG, Choe MS, et al (2005). Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res, 11, 6261-9.